Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3 (NASDAQ:FULC)


Shares of small molecule developer Fulcrum Therapeutics (NASDAQ:FULC) have misplaced greater than 80% of their worth because the IPO was priced at $19 in August 2021. Yr up to now efficiency is destructive 50% after FTX-6058 for sickle cell illness was positioned on full

Back To Top